|
1
|
Niezgoda A, Niezgoda P and Czajkowski R:
Novel approaches to treatment of advanced melanoma: A review on
targeted therapy and immunotherapy. BioMed Res Int.
2015:8513872015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Johnson DB and Sosman JA: Therapeutic
advances and treatment options in metastatic melanoma. JAMA Oncol.
1:380–386. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maverakis E, Cornelius LA, Bowen GM, Phan
T, Patel FB, Fitzmaurice S, He Y, Burrall B, Duong C, Kloxin AM, et
al: Metastatic melanoma - a review of current and future treatment
options. Acta Derm Venereol. 95:516–524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Galper J, Rayner SL, Hogan AL, Fifita JA,
Lee A, Chung RS, Blair IP and Yang S: Cyclin F: A component of an
E3 ubiquitin ligase complex with roles in neurodegeneration and
cancer. Int J Biochem Cell Biol. 89:216–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
D'Angiolella V, Donato V, Forrester FM,
Jeong YT, Pellacani C, Kudo Y, Saraf A, Florens L, Washburn MP and
Pagano M: Cyclin F-mediated degradation of ribonucleotide reductase
M2 controls genome integrity and DNA repair. Cell. 149:1023–1034.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Grolmusz VK, Karászi K, Micsik T, Tóth EA,
Mészáros K, Karvaly G, Barna G, Szabó PM, Baghy K, Matkó J, et al:
Cell cycle dependent RRM2 may serve as proliferation marker and
pharmaceutical target in adrenocortical cancer. Am J Cancer Res.
6:2041–2053. 2016.PubMed/NCBI
|
|
7
|
Han P, Lin Z-R, Xu L-H, Zhong Q, Zhu XF,
Liang FY, Cai Q, Huang XM and Zeng MS: Ribonucleotide reductase M2
subunit expression and prognostic value in nasopharyngeal
carcinoma. Mol Med Rep. 12:401–409. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Aird KM, Zhang G, Li H, Tu Z, Bitler BG,
Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M, et al: Suppression of
nucleotide metabolism underlies the establishment and maintenance
of oncogene-induced senescence. Cell Reports. 3:1252–1265. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mah V, Alavi M, Márquez-Garbán DC, Maresh
EL, Kim SR, Horvath S, Bagryanova L, Huerta-Yepez S, Chia D,
Pietras R, et al: Ribonucleotide reductase subunit M2 predicts
survival in subgroups of patients with non-small cell lung
carcinoma: Effects of gender and smoking status. PLoS One.
10:e01276002015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cerami E, Gao J, Dogrusoz U, Gross BE,
Sumer SO, Aksoy BA, Jacobsen A, Byrne CJ, Heuer ML, Larsson E, et
al: The cBio cancer genomics portal: An open platform for exploring
multidimensional cancer genomics data. Cancer Discov. 2:401–404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fatkhutdinov N, Sproesser K, Krepler C,
Liu Q, Brafford PA, Herlyn M, Aird KM and Zhang R: Targeting RRM2
and mutant BRAF is a novel combinatorial strategy for melanoma. Mol
Cancer Res. 14:767–775. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zuckerman JE, Hsueh T, Koya RC, Davis ME
and Ribas A: siRNA knockdown of ribonucleotide reductase inhibits
melanoma cell line proliferation alone or synergistically with
temozolomide. J Invest Dermatol. 131:453–460. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Fu J, Qiu H, Cai M, Pan Y, Cao Y, Liu L,
Yun J and Zhang CZ: Low cyclin F expression in hepatocellular
carcinoma associates with poor differentiation and unfavorable
prognosis. Cancer Sci. 104:508–515. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sun X, Zhangyuan G, Shi L, Wang Y, Sun B
and Ding Q: Prognostic and clinicopathological significance of
cyclin B expression in patients with breast cancer: A
meta-analysis. Medicine (Baltimore). 96:e68602017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li W, Dong Q, Li L, Zhang Z, Cai X and Pan
X: Prognostic significance of claudin-1 and cyclin B1 protein
expression in patients with hypopharyngeal squamous cell carcinoma.
Oncol Lett. 11:2995–3002. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fang Y, Liang X, Jiang W, Li J, Xu J and
Cai X: Cyclin b1 suppresses colorectal cancer invasion and
metastasis by regulating e-cadherin. PLoS One. 10:e01268752015.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Shan YS, Hsu HP, Lai MD, Hung YH, Wang CY,
Yen MC and Chen YL: Cyclin D1 overexpression correlates with poor
tumor differentiation and prognosis in gastric cancer. Oncol Lett.
14:4517–4526. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin RJ, Lubpairee T, Liu KY, Anderson DW,
Durham S and Poh CF: Cyclin D1 overexpression is associated with
poor prognosis in oropharyngeal cancer. J Otolaryngol Head Neck
Surg. 42:232013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ahlin C, Lundgren C, Embretsén-Varro E,
Jirström K, Blomqvist C and Fjällskog ML: High expression of cyclin
D1 is associated to high proliferation rate and increased risk of
mortality in women with ER-positive but not in ER-negative breast
cancers. Breast Cancer Res Treat. 164:667–678. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Luhtala S, Staff S, Tanner M and Isola J:
Cyclin E amplification, over-expression, and relapse-free survival
in HER-2-positive primary breast cancer. Tumour Biol. 37:9813–9823.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhou YJ, Xie YT, Gu J, Yan L, Guan GX and
Liu X: Overexpression of cyclin E isoforms correlates with poor
prognosis in rectal cancer. Eur J Surg Oncol. 37:1078–1084. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huang L, Ren F, Tang R, Feng Z and Chen G:
Prognostic value of expression of cyclin E in gastrointestinal
cancer: A systematic review and meta-analysis. Technol Cancer Res
Treat. 15:12–19. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
D'Angiolella V, Donato V, Vijayakumar S,
Saraf A, Florens L, Washburn MP, Dynlacht B and Pagano M:
SCF(Cyclin F) controls centrosome homeostasis and mitotic fidelity
through CP110 degradation. Nature. 466:138–142. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Walter D, Hoffmann S, Komseli E-S,
Rappsilber J, Gorgoulis V and Sørensen CS: SCF(Cyclin F)-dependent
degradation of CDC6 suppresses DNA re-replication. Nat Commun.
7:105302016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pan D, Chen Y, Du Y, Ren Z, Li X and Hu B:
Methylation of promoter of RBL1 enhances the radioresistance of
three dimensional cultured carcinoma cells. Oncotarget.
8:4422–4435. 2017.PubMed/NCBI
|
|
26
|
Schoeftner S, Scarola M, Comisso E,
Schneider C and Benetti R: An Oct4-pRb axis, controlled by MiR-335,
integrates stem cell self-renewal and cell cycle control. Stem
Cells. 31:717–728. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Comisso E, Scarola M, Rosso M, Piazza S,
Marzinotto S, Ciani Y, Orsaria M, Mariuzzi L, Schneider C,
Schoeftner S, et al: OCT4 controls mitotic stability and
inactivates the RB tumor suppressor pathway to enhance ovarian
cancer aggressiveness. Oncogene. 36:4253–4266. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Choudhury R, Bonacci T, Wang X, Truong A,
Arceci A, Zhang Y, Mills CA, Kernan JL, Liu P and Emanuele MJ: The
E3 ubiquitin ligase SCF(cyclin F) transmits AKT signaling to the
cell-cycle machinery. Cell Reports. 20:3212–3222. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Choudhury R, Bonacci T, Arceci A, Lahiri
D, Mills CA, Kernan JL, Branigan TB, DeCaprio JA, Burke DJ and
Emanuele MJ: APC/C and SCF(cyclin F) constitute a reciprocal
feedback circuit controlling S-phase entry. Cell Reports.
16:3359–3372. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li Chew C, Lunardi A, Gulluni F, Ruan DT,
Chen M, Salmena L, Nishino M, Papa A, Ng C, Fung J, et al: In vivo
role of INPP4B in tumor and metastasis suppression through
regulation of PI3K-AKT signaling at endosomes. Cancer Discov.
5:740–751. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Perez-Lorenzo R, Gill KZ, Shen C-H, Zhao
FX, Zheng B, Schulze HJ, Silvers DN, Brunner G and Horst BA: A
tumor suppressor function for the lipid phosphatase INPP4B in
melanocytic neoplasms. J Invest Dermatol. 134:1359–1368. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chi MN, Guo ST, Wilmott JS, Guo XY, Yan
XG, Wang CY, Liu XY, Jin L, Tseng HY, Liu T, et al: INPP4B is
upregulated and functions as an oncogenic driver through SGK3 in a
subset of melanomas. Oncotarget. 6:39891–39907. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Akman A, Ciftcioglu MA, Ozbey C and Alpsoy
E: Expression of cell cycle inhibitor p27Kip1 in nevi and
melanomas. Indian J Dermatol Venereol Leprol. 74:5512008.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Flørenes VA, Maelandsmo GM, Kerbel RS,
Slingerland JM, Nesland JM and Holm R: Protein expression of the
cell-cycle inhibitor p27Kip1 in malignant melanoma: Inverse
correlation with disease-free survival. Am J Pathol. 153:305–312.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ivan D, Diwan AH, Esteva FJ and Prieto VG:
Expression of cell cycle inhibitor p27Kip1 and its inactivator Jab1
in melanocytic lesions. Mod Pathol. 17:811–818. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Georgieva J, Sinha P and Schadendorf D:
Expression of cyclins and cyclin dependent kinases in human benign
and malignant melanocytic lesions. J Clin Pathol. 54:229–235. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Bales E, Mills L, Milam N, McGahren-Murray
M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ,
Bar-Eli M, et al: The low molecular weight cyclin E isoforms
augment angiogenesis and metastasis of human melanoma cells in
vivo. Cancer Res. 65:692–697. 2005.PubMed/NCBI
|
|
38
|
Lu M, Breyssens H, Salter V, Zhong S, Hu
Y, Baer C, Ratnayaka I, Sullivan A, Brown NR, Endicott J, et al:
Restoring p53 function in human melanoma cells by inhibiting MDM2
and cyclin B1/CDK1-phosphorylated nuclear iASPP. Cancer Cell.
23:618–633. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kedinger V, Meulle A, Zounib O, Bonnet ME,
Gossart JB, Benoit E, Messmer M, Shankaranarayanan P, Behr JP,
Erbacher P, et al: Sticky siRNAs targeting survivin and cyclin B1
exert an antitumoral effect on melanoma subcutaneous xenografts and
lung metastases. BMC Cancer. 13:3382013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kruiswijk F, Hasenfuss SC, Sivapatham R,
Baar MP, Putavet D, Naipal KA, van den Broek NJ, Kruit W, van der
Spek PJ, van Gent DC, et al: Targeted inhibition of metastatic
melanoma through interference with Pin1-FOXM1 signaling. Oncogene.
35:2166–2177. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ni D, Ma X, Li H-Z, Gao Y, Li XT, Zhang Y,
Ai Q, Zhang P, Song EL, Huang QB, et al: Downregulation of FOXO3a
promotes tumor metastasis and is associated with metastasis-free
survival of patients with clear cell renal cell carcinoma. Clin
Cancer Res. 20:1779–1790. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zanella F, Renner O, García B, Callejas S,
Dopazo A, Peregrina S, Carnero A and Link W: Human TRIB2 is a
repressor of FOXO that contributes to the malignant phenotype of
melanoma cells. Oncogene. 29:2973–2982. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ayuso MI, Hernández-Jiménez M, Martín ME,
Salinas M and Alcázar A: New hierarchical phosphorylation pathway
of the translational repressor eIF4E-binding protein 1 (4E-BP1) in
ischemia-reperfusion stress. J Biol Chem. 285:34355–34363. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sherrill KW, Byrd MP, Van Eden ME and
Lloyd RE: BCL-2 translation is mediated via internal ribosome entry
during cell stress. J Biol Chem. 279:29066–29074. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Qin X, Jiang B and Zhang Y: 4E-BP1, a
multifactor regulated multifunctional protein. Cell Cycle.
15:781–786. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
O'Reilly KE, Warycha M, Davies MA, Rodrik
V, Zhou XK, Yee H, Polsky D, Pavlick AC, Rosen N, Bhardwaj N, et
al: Phosphorylated 4E-BP1 is associated with poor survival in
melanoma. Clin Cancer Res. 15:2872–2878. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dankert JF, Rona G, Clijsters L, Geter P,
Skaar JR, Bermudez-Hernandez K, Sassani E, Fenyö D, Ueberheide B,
Schneider R, et al: Cyclin F-mediated degradation of SLBP limits
H2A.X accumulation and apoptosis upon genotoxic stress in G2. Mol
Cell. 64:507–519. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ang M-K, Patel MR, Yin X-Y, Sundaram S,
Fritchie K, Zhao N, Liu Y, Freemerman AJ, Wilkerson MD, Walter V,
et al: High XRCC1 protein expression is associated with poorer
survival in patients with head and neck squamous cell carcinoma.
Clin Cancer Res. 17:6542–6552. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Batar B, Guven G, Eroz S, Bese NS and
Guven M: Decreased DNA repair gene XRCC1 expression is associated
with radiotherapy-induced acute side effects in breast cancer
patients. Gene. 582:33–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Bhandaru M, Martinka M, Li G and Rotte A:
Loss of XRCC1 confers a metastatic phenotype to melanoma cells and
is associated with poor survival in patients with melanoma. Pigment
Cell Melanoma Res. 27:366–375. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang YM, Wu FJ, Du L, Li GY, Takahashi K,
Xue Y and Xue CH: Effects of polysaccharides from abalone (Haliotis
discus hannai Ino) on HepG2 cell proliferation. Int J Biol
Macromol. 66:354–361. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Miller LD, Coffman LG, Chou JW, Black MA,
Bergh J, D'Agostino R Jr, Torti SV and Torti FM: An iron regulatory
gene signature predicts outcome in breast cancer. Cancer Res.
71:6728–6737. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Laube F and Glanz D: Modulation of
Melanotransferrin and Transferrin Receptor 1 (TFRC)- and CD44-based
Signaling for TFRC Up-regulation in Human Melanoma Cells.
Anticancer Res. 37:3001–3007. 2017.PubMed/NCBI
|
|
54
|
Ryschich E, Huszty G, Knaebel HP, Hartel
M, Büchler MW and Schmidt J: Transferrin receptor is a marker of
malignant phenotype in human pancreatic cancer and in
neuroendocrine carcinoma of the pancreas. Eur J Cancer.
40:1418–1422. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Grzywa TM, Paskal W and Włodarski PK:
Intratumor and Intertumor Heterogeneity in Melanoma. Transl Oncol.
10:956–975. 2017. View Article : Google Scholar : PubMed/NCBI
|
